Advanced endoscopy imaging in inflammatory bowel diseases - 20/04/17
Abstract |
Background and Aims |
Rapid assessment of mucosal inflammation is of crucial importance for the initial diagnosis and the assessment of mucosal healing in inflammatory bowel disease (IBD). Moreover, the identification of intraepithelial neoplasias in IBD is of key relevance for clinical management. Here, we systematically analyzed the utility of advanced endoscopic imaging techniques for optimized diagnosis in IBD.
Methods |
PubMed/Medline, Web of Knowledge, and Cochrane library were searched twice for diagnostic studies on advanced endoscopic imaging in IBD. Clinical and technical information was retrieved and subsequently analyzed. Main outcome parameters consisted of the quality of the results, adverse events, and diagnostic yield.
Results |
Fifty-six clinical studies with a total of 3296 patients were selected for final analysis. Filter technologies permitted a more detailed analysis of mucosal inflammation in IBD. In spite of substantial heterogeneity across studies, dye-based chromoendoscopy with targeted biopsy sampling yielded higher detection rates of intraepithelial neoplasias in ulcerative colitis as compared with white-light endoscopy with random biopsy sampling. Moreover, endocytoscopy and endomicroscopy allowed subsurface imaging of inflamed or neoplastic mucosa in IBD at subcellular resolution. Finally, endomicroscopy-aided molecular imaging enabled the identification of membrane-bound tumor necrosis factor on mucosal cells as a potential driver of disease activity in Crohn's disease. No relevant adverse events were reported.
Conclusions |
Advanced endoscopic imaging technologies are feasible, safe, and partially effective tools for detailed diagnosis of mucosal inflammation and detection of neoplasias in IBD. Results obtained from these advanced techniques may provide a rational basis for individualized, optimized therapy for IBD patients.
Le texte complet de cet article est disponible en PDF.Abbreviations : AFI, CD, CE, CLE, GMP, IBD, iCE, iCLE, IN, mCE, ME, NBI, pCLE, PSC, UC, WLE
Plan
| DISCLOSURE: The following author received research support for this study from the ELAN and IZKF programs in Erlangen, the DFG research group 257, the Emerging Field Initiative, and the DFG collaborative research centers 643, 796, and 1181: M. F. Neurath. In addition, the following author disclosed financial relationships relevant to this publication: M. F. Neurath: Advisor for Pentax, Giuliani, MSD, Abbvie, Janssen, Takeda, and Boehringer. All other authors disclosed no financial relationships relevant to this publication. |
|
| If you would like to chat with an author of this article, you may contact Dr Neurath at Markus.Neurath@uk-erlangen.de. |
Vol 85 - N° 3
P. 496-508 - mars 2017 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
